[Use of cytosar (cytosine arabinoside) in the control of herpetic complications in patients with acute leukemia and lymphogranulomatosis].
The authors report the use of the cytostatic drug cytosar in the control of herpetic complications in patients with acute leukemia and lymphogranulomatosis. A distinct effect was obtained as a result of intravenous drip of cytosar in a dose of 0.03-0.05 g for 2 days. It is desirable that cytosar therapy may be instituted within the first days of the development of herpetic infection.
D000293:Adolescent; D000368:Aged; D002644:Chickenpox / Q000188:drug therapy* / Q000209:etiology; D002675:Child, Preschool; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D006562:Herpes Zoster / Q000188:drug therapy* / Q000209:etiology; D006689:Hodgkin Disease / Q000150:complications*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000150:complications*; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D008297:Male
D003561:Cytarabine
O primenenii tsitozara (tsitozina-arabinozida) dlia bor'by s gerpeticheskimi oslozhneniiami u bol'nykh ostrym leĭkozom i limfogranulematozom.